Literature DB >> 32016065

Cytoreductive nephrectomy following treatment with anti-vascular endothelial growth factor-targeted agents: is it surgically safe?

Hideaki Miyake1.   

Abstract

Entities:  

Year:  2019        PMID: 32016065      PMCID: PMC6976473          DOI: 10.21037/atm.2019.09.106

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


× No keyword cloud information.
  15 in total

1.  Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer.

Authors:  R C Flanigan; S E Salmon; B A Blumenstein; S I Bearman; V Roy; P C McGrath; J R Caton; N Munshi; E D Crawford
Journal:  N Engl J Med       Date:  2001-12-06       Impact factor: 91.245

2.  Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME).

Authors:  Roderick Emile De Bruijn; Peter Mulders; Michael A Jewett; John Wagstaff; Johan V Van Thienen; Christian U Blank; Roland Van Velthoven; Lori Wood; Harm E van Melick; Maureen J Aarts; Jean B Lattouf; Thomas Powles; Igle J De Jong; Sylvie Rottey; Betrand Tombal; Sandrine Marreaud; Sandra Collette; Laurence Collette; John B Haanen; Axel Bex
Journal:  Eur Urol       Date:  2019-06-18       Impact factor: 20.096

3.  Performing cytoreductive nephrectomy following targeted sunitinib therapy for metastatic renal cell carcinoma: a surgical perspective.

Authors:  Greg L Shaw; Mahreen Hussain; Rajesh Nair; John Bycroft; Luis Beltran; James S A Green; Thomas Powles; John L Peters
Journal:  Urol Int       Date:  2012-05-16       Impact factor: 2.089

4.  Updated European Association of Urology Guidelines for Cytoreductive Nephrectomy in Patients with Synchronous Metastatic Clear-cell Renal Cell Carcinoma.

Authors:  Axel Bex; Laurence Albiges; Börje Ljungberg; Karim Bensalah; Saeed Dabestani; Rachel H Giles; Fabian Hofmann; Milan Hora; Markus A Kuczyk; Thomas B Lam; Lorenzo Marconi; Axel S Merseburger; Sergio Fernández-Pello; Rana Tahbaz; Yasmin Abu-Ghanem; Michael Staehler; Alessandro Volpe; Thomas Powles
Journal:  Eur Urol       Date:  2018-08-31       Impact factor: 20.096

5.  Surgical resection of renal cell carcinoma after targeted therapy.

Authors:  Anil A Thomas; Brian I Rini; Andrew J Stephenson; Jorge A Garcia; Amr Fergany; Venkatesh Krishnamurthi; Andrew C Novick; Inderbir S Gill; Eric A Klein; Ming Zhou; Steven C Campbell
Journal:  J Urol       Date:  2009-07-17       Impact factor: 7.450

6.  Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma.

Authors:  Vitaly Margulis; Surena F Matin; Nizar Tannir; Pheroze Tamboli; David A Swanson; Eric Jonasch; Christopher G Wood
Journal:  J Urol       Date:  2008-05-15       Impact factor: 7.450

7.  Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.

Authors:  Arnaud Méjean; Alain Ravaud; Simon Thezenas; Sandra Colas; Jean-Baptiste Beauval; Karim Bensalah; Lionnel Geoffrois; Antoine Thiery-Vuillemin; Luc Cormier; Hervé Lang; Laurent Guy; Gwenaelle Gravis; Frederic Rolland; Claude Linassier; Eric Lechevallier; Christian Beisland; Michael Aitchison; Stephane Oudard; Jean-Jacques Patard; Christine Theodore; Christine Chevreau; Brigitte Laguerre; Jacques Hubert; Marine Gross-Goupil; Jean-Christophe Bernhard; Laurence Albiges; Marc-Olivier Timsit; Thierry Lebret; Bernard Escudier
Journal:  N Engl J Med       Date:  2018-06-03       Impact factor: 91.245

8.  Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.

Authors:  Axel Bex; Peter Mulders; Michael Jewett; John Wagstaff; Johannes V van Thienen; Christian U Blank; Roland van Velthoven; Maria Del Pilar Laguna; Lori Wood; Harm H E van Melick; Maureen J Aarts; J B Lattouf; Thomas Powles; Igle Jan de Jong Md PhD; Sylvie Rottey; Bertrand Tombal; Sandrine Marreaud; Sandra Collette; Laurence Collette; John Haanen
Journal:  JAMA Oncol       Date:  2019-02-01       Impact factor: 31.777

Review 9.  Systemic therapy in metastatic renal cell carcinoma.

Authors:  Jens Bedke; Thomas Gauler; Viktor Grünwald; Axel Hegele; Edwin Herrmann; Stefan Hinz; Jan Janssen; Stephan Schmitz; Martin Schostak; Hans Tesch; Stefan Zastrow; Kurt Miller
Journal:  World J Urol       Date:  2016-06-09       Impact factor: 4.226

10.  Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal Cancer.

Authors:  Thomas Powles; Naveed Sarwar; Andrew Stockdale; Shah-Jalal Sarker; Ekaterini Boleti; Andrew Protheroe; Robert Jones; Simon Chowdhury; John Peters; Grenville Oades; Tim O'Brien; Mark Sullivan; Michael Aitchison; Luis Beltran; Daniel Worth; Kate Smith; Constance Michel; Giorgia Trevisan; Elizabeth Harvey-Jones; Akhila Wimalasingham; Anju Sahdev; Charlotte Ackerman; Simon Crabb
Journal:  JAMA Oncol       Date:  2016-10-01       Impact factor: 31.777

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.